Souhaitez-vous accéder aux communiqués récents ?

Claret Capital Partners, Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28m

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...

CMMB CEO Dr. Adi Mor will present at Oppenheimer's virtual 36th Annual Life Sciences Healthcare Conference on Feb. 26 at 8:00 am ET.

Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory HSV

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock